FDA looking to get scientific about the effects of cannabis based on gender differences

8w
3m read
Summary

It has also continued to send warnings to cannabis businesses and provide public notices about recalls. Subscribe to the Cannabis Post newsletter for weekly insights into the industry, what insiders will be talking about and content from across the Postmedia Network. Want to keep up to date on what’s happening in the world of cannabis? The FDA “strongly advises against” using CBD, THC and cannabis in any form during pregnancy or while breastfeeding. / Photo: iStock / Getty Images Plus That advice, though, does not jibe with the behaviour of some women. The FDA “strongly advises against” using CBD, THC and cannabis in any form during pregnancy or while breastfeeding, notes an agency fact sheet. “FDA wants you to know there may be serious risks to using cannabis products, including those containing CBD, if you are pregnant or breastfeeding,” it adds.

Article Preview

The U.S. Food and Drug Administration (FDA) is hoping current agency efforts coupled with public input will help pin down how best to account for the effects of sex and gender differences in the wake of skyrocketing interest in cannabis and hemp derivatives, as well as burgeoning dubious claims around their efficacy.

The FDA has announced it will hold a public meeting on Nov. 19, one that it suggests will be of benefit to researchers, educators, clinicians and patients with an interest in CBD and other cannabinoids. Experts in cannabinoid research, education...

Read the full article @ The Growth Op